CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that much of the pipeline remains undervalued and noted that the company could begin late-stage development for up to seven opportunities in 2027. Earlier on January 6, Bank of America analyst Alec Stranahan reduced the firm’s price target for CRISPR Therapeutics (NASDAQ:CRSP) ...

On January 27, Sherry Paul, Morgan Stanley senior portfolio manager, joined CNBC’s ‘Closing Bell’ to discuss the state of equity markets and whether more volatility is ahead. Pre-Davos market was characterized by overwhelming bullish sentiment, and the post-Davos environment is marked by renewed volatility, the Sell-America trade, a rallying gold price, and a consistently weak dollar. Paul noted a critical shift in global discourse coming out of Davos: the transition from the term de-globalization to the ne ...

Core Insights - CRISPR Therapeutics (CRSP) is expected to exceed expectations in its fourth-quarter and full-year 2025 results, with earnings having beaten estimates by 11.36% in the last reported quarter [1] - The Zacks Consensus Estimate for quarterly sales is $4.00 million, while the earnings estimate is a loss of $1.15 per share [1] Financial Performance - CRISPR Therapeutics' revenue includes grants and collaboration income from its partnership with Vertex Pharmaceuticals (VRTX) [2] - The company has shown a decent performance over the past four quarters, beating earnings estimates in three of those quarters, with an average surprise of 15.23% [8] Product Development - The one-shot gene therapy, Casgevy, developed in partnership with VRTX, was approved for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in late 2023/early 2024, marking it as the only marketed product in CRISPR's portfolio [3] - Casgevy sales have been increasing, which is likely to improve collaboration expenses for the upcoming quarter [4] Future Prospects - Investors are keen on updates regarding global regulatory submissions planned for the first half of 2026, aiming for label expansion of Casgevy for younger patients [5] - CRISPR Therapeutics is developing novel CAR-T cell therapies, including zugo-cel, which is being evaluated in early-stage studies for various conditions [6] - The company is also advancing its in-vivo pipeline with candidates CTX310 and CTX320, and plans to introduce two more programs, CTX340 and CTX450, into clinical development by the end of the year [7] Earnings Prediction - The model predicts an earnings beat for CRISPR Therapeutics, supported by a positive Earnings ESP of +15.85% and a Zacks Rank of 3 [11][12] - The Most Accurate Estimate stands at a loss of $0.97 per share, compared to the Zacks Consensus Estimate of a loss of $1.15 [12]

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. BofA is Bullish on CRISPR Therapeutics AG (CRSP) On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating. Casgevy’s 2026 projections were slightly lowered as a result of the modification. Based on an earnings preview paper covering the biotechnology group, BofA still pro ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP) , has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.The company, which often features at the top of several funds managed by Cathie Wood’s Ark Invest, such as the Ark Innovation ETF (BATS:ARKK) and the Ark Genomic Revolution ETF (BATS:ARKG) , is seeing its Momentum score slide over the past couple of days.Biotech Stock Sees Momentum SlideThe Momentum score ...

CEO Samarth Kulkarni sold 60,000 shares, impacting CRISPR Therapeutics AG's (NASDAQ:CRSP) stock performance.The stock experienced a 4.71% decline recently, contrasting with the broader market's gains.Upcoming earnings report expected to show a significant decrease in EPS and revenue, highlighting financial challenges.CRISPR Therapeutics AG (NASDAQ:CRSP) is a biotechnology company focused on developing transformative gene-based medicines. The company is a leader in CRISPR/Cas9 gene-editing technology, which ...

Core Viewpoint - Concerns about an AI bubble may lead to a slowdown in market gains, but Cathie Wood believes a "Golden Age" for markets is possible in the next three years due to a favorable business environment under the Trump administration [1][6]. Economic Projections - Wood predicts that falling interest rates, tax cuts, and deregulation, which she describes as "Reaganomics on steroids," could result in U.S. GDP growth accelerating to 6% to 8% annually in the coming years [2]. Investment Focus - Cathie Wood's investment strategy emphasizes companies that are at the forefront of industry-disrupting innovations, particularly in technology, which has garnered her a significant following in the tech investment community [3]. - Heavy capital spending by major U.S. companies is expected to lead to productivity boosts driven by technological advancements, including AI, with operational costs for running models anticipated to decline [3]. Technological Developments - Advancements in AI, robotics, energy storage, blockchain, and biological technology are expected to drive productivity growth to new sustainable highs and create significant wealth [4]. Market Outlook - Wood's outlook for 2026 is more optimistic than many Wall Street analysts, who expect more modest gains for the S&P 500 compared to last year, although she did not provide a specific target for the index [4]. Performance of ARK Innovation ETF - The ARK Innovation ETF (ARKK), which includes major holdings like Tesla, Crispr Therapeutics, Roku, and Coinbase, achieved a total return of approximately 35% last year, outperforming the S&P 500's 18% return [5].

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.21, marking a -4.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%. Prior to today's trading, shares of the company had gained 3.93% outpaced the Medical sector's gain of 0.92% and the S&P 500's gain of 1.57%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming ea ...

Core Insights - The individual has extensive experience in finance, having worked as a Senior Manager at a Big Four accounting firm and as a CFO for two privately held companies in the aerospace and defense and beauty industries [1] - The investment philosophy leans towards value investing, particularly favoring the Buffett/Munger approach of acquiring quality businesses at fair prices while remaining open to various investment ideas [1] - Emphasis is placed on thorough research and continuous monitoring of investments, including quarterly financial reviews and staying updated with relevant news [1] Company Insights - The companies involved have sales ranging from $50 million to $100 million, indicating a focus on mid-sized enterprises within their respective industries [1] - The aerospace and defense sector, along with the beauty industry, are highlighted as key areas of investment interest, suggesting potential growth opportunities in these markets [1] Investment Strategy - The strategy involves a long-term holding approach, with a preference for reinvesting dividends rather than frequent trading, which aligns with a value investing mindset [1] - Acknowledgment of both positive aspects and risks associated with investments is crucial, as it reflects a balanced perspective on market dynamics [1]

Core Viewpoint - The individual emphasizes the importance of thorough research and ongoing monitoring of investments, advocating for a value investing approach similar to that of Buffett and Munger [1] Group 1: Investment Philosophy - The company adopts a value investing philosophy, focusing on acquiring high-quality businesses at fair prices [1] - The investment strategy includes a preference for holding investments long-term and reinvesting dividends rather than frequent trading [1] Group 2: Research and Analysis - The company conducts extensive research not only prior to investing but also continuously throughout the investment's lifecycle [1] - Regular financial checkups, participation in conference calls, and staying updated with news are integral to the investment process [1] Group 3: Market Experience - The individual has experienced various market cycles since 1999, which informs their investment decisions and strategies [1] - The company recognizes the dual nature of investments, acknowledging both potential positives and inherent risks [1]